{
    "clinical_study": {
        "@rank": "97357", 
        "acronym": "ARAFOR", 
        "arm_group": [
            {
                "arm_group_label": "ODM-201 Tablet A", 
                "arm_group_type": "Experimental", 
                "description": "ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order."
            }, 
            {
                "arm_group_label": "ODM-201 Tablet B", 
                "arm_group_type": "Experimental", 
                "description": "ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order."
            }
        ], 
        "brief_summary": {
            "textblock": "A study to investigate which of two different tablet formulations of ODM-201 is best suited\n      for use in the further development of the compound in the treatment of metastatic\n      chemotherapy-naive castration-resistant prostate cancer. Patients successfully completing\n      the bioavailability study will be able to receive further treatment with the current capsule\n      formulation of ODM-201 until progression of their disease with the safety and tolerability\n      of ODM-201 being assessed throughout."
        }, 
        "brief_title": "Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent (IC) obtained.\n\n          -  Histologically confirmed  adenocarcinoma of prostate\n\n          -  Progressive metastatic disease\n\n          -  Ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone\n             (LHRH) analogue or antagonist or bilateral orchiectomy\n\n          -  Adequate bone marrow, hepatic and renal function\n\n          -  Able to swallow the ODM-201 whole as a capsule or tablet.\n\n        Exclusion Criteria:\n\n          -  Previous chemotherapy for prostate cancer.\n\n          -  Known metastases in the brain.\n\n          -  History of other malignancy within the previous 5 years, except a basal cell\n             carcinoma of skin.\n\n          -  Known gastrointestinal condition that can significantly affect the absorption of the\n             study treatment."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01784757", 
            "org_study_id": "3104003", 
            "secondary_id": "2012-002279-32"
        }, 
        "intervention": [
            {
                "arm_group_label": "ODM-201 Tablet A", 
                "description": "Tablet A formulation of ODM-201", 
                "intervention_name": "ODM-201 Tablet A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ODM-201 Tablet B", 
                "description": "Tablet B formulation of ODM-201", 
                "intervention_name": "ODM-201 Tablet B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ODM-201 Tablet A", 
                    "ODM-201 Tablet B"
                ], 
                "description": "Capsule formulation of ODM-201", 
                "intervention_name": "ODM-201 capsule formulation", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Riga", 
                    "country": "Latvia"
                }, 
                "name": "P. Stradina Clinical University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Latvia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer", 
        "overall_official": {
            "affiliation": "Institut Gustave Roussy, University of Paris", 
            "last_name": "Karim Fizazi, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Finland: Finnish Medicines Agency", 
                "Finland: Ethics Committee", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes", 
                "Latvia: State Agency of Medicines", 
                "Latvia: Institutional Review Board", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Lithuania: Bioethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The area under the concentration-time curve from time zero to the last sample with the quantifiable concentration calculated with linear trapezoidal rule.", 
                "measure": "Area under the curve (AUC) of ODM-201", 
                "safety_issue": "No", 
                "time_frame": "0-48 hrs"
            }, 
            {
                "description": "The plasma peak concentration.", 
                "measure": "Cmax of ODM-201", 
                "safety_issue": "Yes", 
                "time_frame": "0-48 hrs"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01784757"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The time to reach peak concentration.", 
                "measure": "tmax of ODM-201", 
                "safety_issue": "No", 
                "time_frame": "0-48 hrs"
            }, 
            {
                "description": "The terminal elimination rate constant from log-linear portion of a concentration-time curve.", 
                "measure": "Terminal elimination rate constant of ODM-201", 
                "safety_issue": "No", 
                "time_frame": "0-48 hrs"
            }, 
            {
                "description": "The terminal elimination half-life that will be calculated with the equation ln2/terminal elimination rate constant.", 
                "measure": "Terminal elimination half-life of ODM-201", 
                "safety_issue": "No", 
                "time_frame": "0-48 hrs"
            }
        ], 
        "source": "Orion Corporation, Orion Pharma", 
        "sponsors": {
            "collaborator": {
                "agency": "Endo Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Orion Corporation, Orion Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}